Potrero Hill Therapeutics

Executive Summary

Potrero Hill Therapeutics is a preclinical biopharmaceutical company headquartered in San Francisco, founded in 2020 with a focus on oncology and immunology. Operating with a lean, experienced team, the company aims to advance strong preclinical candidates to early clinical proof-of-concept, emphasizing efficient resource utilization, robust intellectual property creation, and strategic exits through partnerships or acquisitions. While no specific pipeline assets have been publicly disclosed, the company's model and focus on high-value indications position it as a potential player in targeted therapies. Given its early stage, the company's value is contingent on successful preclinical validation, IND filings, and securing partnerships to fund development and de-risk future clinical trials. The cohort of similar early-stage biotechs suggests that near-term milestones will be critical in demonstrating proof-of-concept and attracting further investment.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate IND filing20% success
• Q2 2026Preclinical efficacy data release for lead asset30% success
• TBDPartnership or licensing agreement with larger pharma15% success